Our core research product, “SP-2021A (Anti-Siglec-3 (CD33) antibody for healing Chronic Hepatitis B)” garnered significant attention at the 2022 NBRP DEMO DAY National Biotechnology Research Park investment matchmaking competition. It received the Investor Favor Award, a testament to the recognition of our innovative technology and a vote of confidence in our company's future prospects. This accolade inspires us to seek additional investment partnerships as we continue to drive breakthroughs and advancements in the field of biomedicine.